Analyts Reports

May 18, 2026

Maxim Initiates Coverage on NTHI With a Buy Rating

April 24, 2026

BTIG Initiates Coverage on NTHI With a Buy Rating

News

Stock Information

SEC Filings

Corporate Governance

Investor Inquiries

Investor FAQs

Stay on top of NeOnc’s groundbreaking research,
clinical trials, and our mission to revolutionize CNS therapeutics.

Subscribe To Alerts

Our innovative formulations offer pharmaceutical companies a new pathway to deliver potentially more effective treatments for CNS diseases, expanding possibilities for patients.

Facebook opens in new tab Twitter opens in new tab LinkedIn opens in new tab Instagram opens in new tab

Company

Investor Relations
News
Stock Information
SEC Filings
Corporate Governance
Resources

Quick Links

Privacy Policy
Accessibility Statement
Terms Of Use
Sitemap

Contact

23975 Park Sorrento Suite 205
Calabasas, CA 91302

Need help? Call us

+1 (818) 570-NTHI